NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date:** Thursday 6 June 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Megan John (Chair, Chair of Topics 2 and 3) Present for all items
2. Dr Raju Reddy (Vice-chair, Chair of Topic 1) Present for all items
3. Martin Bradley Present for all items
4. Dr Matthew Bradley Items 1.1 to 4.2.2, Items 6.1 to

6.2.2

1. Paul Caulfield Items 1.1 to 5.2.2
2. Professor Sofia Dias Present for all items
3. Andrew Fox Present for all items
4. Dr Robert Hodgson Present for all items
5. Dr Bernard Khoo Present for all items
6. Dr Guy Makin Present for all items
7. Dr Philip Mallender Present for all items
8. Professor David Meads Present for all items
9. Giles Monnickendam Present for all items
10. Dr Nathan Moore Present for all items
11. Dr Paula Parvulescu Present for all items
12. Dr Ben Searle Present for all items

NICE staff (key players) present

Jacoline Bouvy, Programme Director, Items 1.1 to 4.2.2, Items 6.1 to 6.2.2

Richard Diaz, Associate Director Items 1.1 to 4.2.2

Kate Moore, Project Manager, Items 1.1 to 4.2.2, Items 6.1 to 6.2.2

Mary Hughes, Heath Technology Assessment Adviser Items 1.1 to 4.2.2

Emma Bajela, Heath Technology Assessment Analyst Items 1.1 to 4.2.2

Ross Dent, Associate Director Items 5.1 to 5.2.2

Celia Mayers, Project Manager Items 5.1 to 5.2.2

Christian Griffiths, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

Thomas Jarratt, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

Janet Robertson, Associate Director Items 6.1 to 6.2.2

Adam Brooke, Heath Technology Assessment Adviser Items 6.1 to 6.2.2

Emily Leckenby, Heath Technology Assessment Analyst Items 6.1 to 6.2.2

External assessment group representatives present

Dr Ben Farrar, BMJ Technology Assessment Group Items 1.1 to 4.1.3

Kate Ennis, BMJ Technology Assessment Group Items 1.1 to 4.1.3

Dr Paul Tappenden, Sheffield Centre for Health and Related Research

Items 5.1 to 5.1.3

Sarah Ren, Sheffield Centre for Health and Related Research

Items 5.1 to 5.1.3

Hollie Wheat, Peninsula Technology Assessment Group Items 6.1 to 6.1.3

Dr Caroline Farmer, Peninsula Technology Assessment Group

Items 6.1 to 6.1.3

Clinical, Patient & NHS England experts present

Ross Bennett, Patient expert nominated by the Haemophilia Society

Items 1.1 to 4.1.3

Jefferson Courtney, Policy and Public Affairs Manager, Haemophilia Society, Patient expert nominated by the Haemophilia Society Items 1.1 to 4.1.3

Dr Dalia Khan, Consultant Haematologist, Clinical expert nominated by Pfizer

Items 1.1 to 4.1.3

Dr Charles Percy, Consultant Haematologist, Clinical expert nominated by NHS England Items 1.1 to 4.1.3

Dr Sanjeev Patel, IMF Items 1.1 to 4.2.2

Dr Elizabeth Toy, Consultant Clinical Oncologist – clinical expert, nominated by AstraZeneca Items 5.1 to 5.1.3

Professor Eric Lim, Professor of Thoracic Surgery, clinical expert, nominated by AstraZeneca Items 5.1 to 5.1.3

Dr Gini Harrison, Patient expert, nominated by EGFR Positive UK,

Items 5.1 to 5.1.3

Professor Peter Clark, CDF Lead, NHS England Items 5.1 to 5.2.2

Emma Rush, CEO, Vitiligo Support UK, Patient expert, nominated by Vitiligo Support UK Items 6.1 to 6.1.3

Pav Korpal, Patient expert nominated by Vitiligo Support UK Items 6.1 to 6.1.3

Dr Viktoria Eleftheriadou, Consultant Dermatologist, Clinical expert, nominated by British Association of Dermatologists (BAD) Items 6.1 to 6.1.3

Dr Jonathan Batchelor, Consultant Dermatologist, Clinical expert, nominated by Vitiligo Support UK Items 6.1 to 6.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The Chair, Dr Raju Reddy, welcomed members of the committee and other attendees present to the meeting.
  2. The Chair noted apologies from Carole Pitkeathley, Craig Cook, Sophia Steer, Will Sullivan, and Dr Zenas Yiu.

### News and announcements

* 1. None

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 9 May 2024

### Appraisal of fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]

* 1. Part 1 – Open session
     1. The Chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Pfizer.
     2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11117).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Paul Caulfield, Dr Bernard Khoo, and Philip Mallender.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives, and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11117>

### Appraisal of osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]

* 1. Part 1 – Open session
     1. The Chair, Dr Megan John, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from AstraZeneca.
     2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11369).
     3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Paul Caulfield, Martin Bradley, and Professor Sofia Dias.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives, and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached through a vote by members.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11369>

### Appraisal of ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]

* 1. Part 1 – Open session
     1. The Chair, Dr Megan John, welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Incyte.
     2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10893).
     3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by the Chair.
  2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10893>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be a hybrid meeting held on Wednesday 3 July 2023 and will start promptly at 09:30am.